A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TMDD / target-mediated drug disposition

[Related PubMed/MEDLINE]
Total Number of Papers: 99
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TMDD  (>> Co-occurring Abbreviation)
Long Form:   target-mediated drug disposition
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A full Target-Mediated Drug Disposition (TMDD) model to explain the changes in recombinant human erythropoietin (rhEpo) pharmacokinetics in patients with different bone marrow integrity following hematopoietic transplantation. EPOR, rhEPO
2022 Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition model. QSS
2022 Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fc-fusion Proteins at Pharmacologically Active Doses. Fc, IL-10
2021 A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults. HSD1, PK
2021 A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. EGFR, mAb, PK, PKs
2021 An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases. IBD, LN, SLE
2021 Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR). LFTR
2021 Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included. SSIMs
2021 First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects. AEs, MACO, PTEN
10  2021 Impact of target-mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. ITP, PK
11  2021 Infliximab Efficacy May Be Linked to Full TNF-alpha Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. IBD, QSS
12  2021 Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). FXII, mPBPK, PD, PK
13  2021 Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. BLyS, pcVPC, PopPK, RA, SLE
14  2021 Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics. PD, PK, s.c, TFPI
15  2020 A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib. DDI, PB, PD, RBC
16  2020 Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy. ADC
17  2020 Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen. HL2351, PK
18  2020 Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. MM, RB/QSS, rHuEPO, SSE
19  2020 Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human. DPP-4, PBPK
20  2020 Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-gamma-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing. IP-10, TE
21  2020 Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease. CSF, IgG4, PD, PK
22  2020 Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues. IL-36R, mAb
23  2020 Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. ADPKD, EGFR, PopPK
24  2020 Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase. sEH, TCPU
25  2020 Target-Mediated Drug Disposition-A Class Effect of Soluble Epoxide Hydrolase Inhibitors. sEH
26  2020 Target-mediated exposure enhancement: a previously unexplored limit of TMDD. TMEE
27  2020 Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. ECD, PD, PK, T-DM1
28  2019 Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds. PD, PK
29  2019 Geometric singular perturbation analysis of a dynamical target mediated drug disposition model. ---
30  2019 Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition. EHC, MCT1, PK
31  2019 Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500. FIH, GAS6, PK/PD
32  2019 Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists. ERAs, ET-1, i.v, PK
33  2019 Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. NONMEM, QSS, TNF, UC
34  2018 Asymptotic analysis of a TMDD model: when a reaction contributes to the destruction of its product. CSP, SIMs
35  2018 Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. mAb, PNH
36  2018 General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study. ---
37  2018 Importance of target-mediated drug disposition for small molecules. PK
38  2018 In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody. CI, OSM, PBPK
39  2018 MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues. mPBPK, QSS
40  2018 Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I. CLL, PCSK9, PD, PK, PopPK
41  2018 Predicting the Onset of Nonlinear Pharmacokinetics. PK
42  2018 Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy. bsAbs, QE, TC
43  2017 Capacity limits of asialoglycoprotein receptor-mediated liver targeting. ASGPR
44  2017 Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites. ---
45  2017 Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties. ---
46  2017 Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. CIDBF, PK
47  2017 Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. ADA, PK, s.c
48  2017 Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases. DDI, ODE, QE, QSS
49  2017 Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1. ET-1, ETA and ETB, i.v, PK, PK/PD
50  2017 Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies. PopPK
51  2017 Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations. DDI, QE, QSS
52  2016 A cell-level model of pharmacodynamics-mediated drug disposition. PDMDD, PK
53  2016 Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). LDL-C, PCSK9, PD, PK
54  2016 Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. mAb, mPBPK
55  2016 Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. AML
56  2016 Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview. ---
57  2016 Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody. CL, EGFR, PK, RO
58  2015 A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations. EAR, MM, QE/RB, QSS
59  2015 A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. ---
60  2015 Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. ADME, FIH, mAbs, PBPK, PD, PK
61  2015 Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384. ---
62  2015 Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus. ER, FPG, GLP-1R, HbA1c, PK/PD, T2DM
63  2015 Temporal pharmacokinetic/pharmacodynamic interaction between human CD3epsilon antigen-targeted monoclonal antibody otelixizumab and CD3epsilon binding and expression in human peripheral blood mononuclear cell static culture. mAb, PBMCs, PK/PD, TCR
64  2014 An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. ANC, G-CSF, PD, PK, s.c
65  2014 Biologics: an update and challenge of their pharmacokinetics. ADA, ADCs, ADME, DI, e.g. Fabs, FcgammaR, mAbs, PBPK, PK, Pop-PK, SMs
66  2014 Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. cTMDD, ISF, mAb, mPBPK, PK
67  2014 Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. KPI, s.c
68  2014 Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAFE, BW, mAbs, PK
69  2014 Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. mAbs, PBPK
70  2013 Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design. FIH, MABEL, PD, PK, s.c, TrkB
71  2013 Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors. Hsp90
72  2013 Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys. CD4-BFFI, PD, PK
73  2013 Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. mAbs, PBPK
74  2013 Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys. HCV, i.v, PK
75  2013 Target-mediated drug disposition model and its approximations for antibody-drug conjugates. ADC, PK
76  2012 A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. PK
77  2012 Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. mAb, PD, PK
78  2012 Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. MM, PK, QSS, RB
79  2012 Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. ---
80  2012 Interspecies modeling and prediction of human exenatide pharmacokinetics. s.c
81  2012 Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. ---
82  2012 Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. ---
83  2011 Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. BAYES, FOCEI, IMP, IMPMAP, ITS, SAEM
84  2011 Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target. ---
85  2010 Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. IFN-beta, PK, tot
86  2010 Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. IFNs, PD, PK
87  2010 Target-mediated drug disposition model for drugs that bind to more than one target. mAb, MM, QSS
88  2010 The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. Dkk-1, MABEL, PK, PK/PD, RO
89  2010 Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. IFN, KO, muEPO, PD, PK, WT
90  2009 Dynamics of target-mediated drug disposition. MM, QE, QSS
91  2009 Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. ---
92  2009 Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. ---
93  2009 Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. int, MM, tot
94  2009 Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. PD, PK
95  2009 Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. ---
96  2008 Approximations of the target-mediated drug disposition model and identifiability of model parameters. MM, QE, QSS
97  2007 Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. EpoR, PK, RC
98  2006 Target-mediated drug disposition and dynamics. ---
99  2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. LIF